Trial Profile
A Randomised, Single-Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability, Immunogenicity, Pharmacokinetics and Pharmacodynamics of Intravenous Infusion of GSK933776A in Patients With Alzheimer's Disease.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Jul 2023
Price :
$35
*
At a glance
- Drugs GSK 933776 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors GSK
- 23 Jun 2011 Actual end date (May 2011) added as reported by ClinicalTrials.gov.
- 23 Jun 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 06 Apr 2010 Planned end date changed from 1 Aug 2010 to 1 Nov 2010 as reported by ClinicalTrials.gov.